cancer targeted therapies

The study team included, from left, Douglas Johnson, MD, Dan Roden, MD, Javid Moslehi, MD, Joe-Elie Salem, MD, PhD, and Ali Manouchehri, MD.
September 25, 2019

Study identifies targeted therapy’s cardiac risks

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

By Tom Wilemon